预约演示
更新于：2025-11-19
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2025-11-19
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
50
项与 盐酸尼卡地平 相关的临床试验NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT07044232
NICardipine for Fast Achievement of Systolic BP Targets in ICH
- a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.
NCT06093893
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,795
项与 盐酸尼卡地平 相关的文献（医药）2025-12-01LIFE SCIENCES
Nicardipine protects against gentamicin-induced nephrotoxicity: Potential involvement of IL-23R, NRF2, and Beclin-1 perturbation
Article
作者: Messiha, Basim A.S. ; Ashour, Marwa M.N. ; Sharkawi, Souty M.Z. ; Messiha, Basim A S ; Sharkawi, Souty M Z ; Abd-Eldayem, Ahmed M. ; El-Shoura, Ehab A M ; El-Shoura, Ehab A.M.
AIMS:
Gentamicin (GNT) remains a cornerstone in the treatment of severe Gram-negative infections; however, its clinical utility is constrained by dose-limiting nephrotoxicity. Emerging evidence implicates nicardipine (NIC), a dihydropyridine calcium channel blocker, in renoprotection via mechanisms distinct from its canonical vascular effects. In this study, we delineate an unprecedented nephroprotective mechanism of NIC in the context of GNT-induced renal injury, with a particular focus on its capacity to modulate oxidative stress, inflammatory signaling, autophagic, and apoptotic pathways.
MATERIALS AND METHODS:
Experimental groups comprised control rats, GNT-treated rats, NIC-treated rats, and animals that received NIC + GNT. Renal function was rigorously evaluated through measuring serum creatinine and blood urea nitrogen (BUN), alongside a multidimensional analysis encompassing oxidative stress indices, inflammatory mediators, histopathological alterations, and expression profiles of apoptosis- and autophagy-associated proteins. Mechanistic interrogation centered on nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of antioxidant defense; interleukin-23 receptor (IL-23R), a pivotal mediator of proinflammatory signaling; and Beclin-1, a crucial autophagy-related factor underlying NIC's renoprotective action.
KEY FINDINGS:
Co-administration of NIC markedly ameliorated GNT-induced renal injury, as reflected by improved biochemical indices of kidney function, preservation of renal histoarchitecture, attenuation of caspase-3-mediated apoptosis, upregulation of NRF2-driven antioxidant responses, suppression of IL-23R-dependent inflammatory signaling, and modulation of Beclin-1-associated autophagic activity.
SIGNIFICANCE:
These findings delineate a novel mechanistic axis by which NIC exerts coordinated antioxidant, anti-inflammatory, autophagic, and anti-apoptotic effects. This multifactorial cytoprotection highlights NIC's therapeutic potential for targeted intervention in aminoglycoside-induced nephrotoxicity.
2025-12-01HOSPITAL PHARMACY
Chemical Stability Testing of Solutions for Intraventricular Irrigations via IRRA
flow
Ventricular Drain System
Article
作者: Brandmeir, Nicholas ; DeBastiani, Anthony ; Peaslee, Jessica ; Garavaglia, Jeffrey
Purpose:
Advances have been made with delivery of medications via continuous intrathecal irrigating ventricular drains such as IRRAflow (IRRAS). Medications including vancomycin, tobramycin, daptomycin and nicardipine are currently being used as ventricular irrigations via the IRRAflow device. The purpose of this study was to evaluate the chemical stability of minute concentrations of daptomycin, nicardipine, tobramycin, and vancomycin for administration via IRRAflow intrathecal catheters.
Methods:
Commercially available formulations of daptomycin, nicardipine, tobramycin, and vancomycin were each diluted in separate normal saline (NS) 1000 mL bags to final concentrations of daptomycin 2 mg/1000 mL NS, nicardipine 2.5 mg/1000 mL NS, tobramycin 4 mg/1000 mL NS, and vancomycin 4 mg/1000 mL NS. Samples from each compound were transferred into 2.5 mL glass vials and evaluated in triplicate fashion using ultra-performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). Each injection was analyzed in comparison to its respective calibration curve and a mean result for each time point was determined. The concentration of the samples was tested at 0, 6 and 12-hours for vancomycin, daptomycin, and tobramycin and 0, 4 and 8-hours for nicardipine. All irrigations were kept at room temperature and were not protected from light.
Results:
All samples tested were found to be chemically stable at various testing time points. Daptomycin retained a mean of 94.3% of initial concentration at 12 hours while tobramycin retained 93.1% of its initial concentration at 12 hours. Vancomycin samples were found to be 92.9% of initial concentration at 12 hours and nicardipine maintained a mean of 90.6% of initial concentration at 8 hours. Future studies could assess these conditions to potentially further stability data.
Conclusion:
With use of LC-MS, we demonstrated that dilute concentrations of vancomycin, daptomycin, and tobramycin maintain at least 90% of initial concentration for 12 hours at room temperature, whereas nicardipine remained chemically stable for 8 hours at room temperature.
2025-12-01Toxicology reports
The protective role of nicardipine in dextran sulfate sodium-induced colitis in mice: Modulating inflammation and apoptosis
Article
作者: Al-Joda, Ali M ; Zalzala, Munaf H
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with persistent inflammation, oxidative stress, and epithelial apoptosis. Nicardipine, a dihydropyridine calcium channel blocker, exhibits anti-inflammatory and anti-apoptotic properties, but its therapeutic potential in UC remains unclear. This study evaluated the effects of nicardipine on dextran sulfate sodium (DSS)-induced colitis in mice, focusing on inflammatory, oxidative, and apoptotic pathways. Fifty BALB/c mice were assigned to five groups (n = 10): control, DSS, nicardipine 12 mg/kg, nicardipine 24 mg/kg, and 5-aminosalicylate (ASA) 75 mg/kg. Treatments were administered for 3 days before and 10 days during DSS exposure. Disease severity was assessed by body weight, disease activity index (DAI), and colon length. Colonic mRNA levels of Nlrp3, TNF-α, IL-17, and TNFSF10 were quantified by RT-PCR; protein expression of caspase-3, caspase-8, BAX, and BCL-2 was analyzed by Western blot. Serum malondialdehyde (MDA), myeloperoxidase (MPO), glutathione peroxidase-1 (GPX-1), occludin, and prostaglandin E₂ (PGE-2) were measured by ELISA. Histological scoring assessed epithelial integrity and inflammation. Nicardipine dose-dependently reduced DSS-induced weight loss, DAI, and colon shortening. Both doses significantly downregulated Nlrp3, TNF-α, IL-17, and TNFSF10 (p < 0.05), decreased caspase-3 and BAX, and increased BCL-2. Nicardipine restored GPX-1, lowered MDA and MPO, preserved occludin, and reduced PGE-2. Histology confirmed reduced mucosal injury and preserved epithelial architecture. Nicardipine attenuates DSS-induced colitis by suppressing pro-inflammatory cytokines, reducing oxidative stress, and inhibiting apoptosis, supporting its potential as a therapeutic candidate for UC. Further studies are warranted to clarify its molecular mechanisms and clinical relevance.
93
项与 盐酸尼卡地平 相关的新闻（医药）2025-11-05
抗体药物偶联物AACR会议财报蛋白降解靶向嵌合体临床申请
2025-11-02
·信狐药迅
抗体药物偶联物申请上市
2025-10-30
申请上市高管变更临床申请
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1998-01-01 | |
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 术中高血压 | 日本 | 1988-09-20 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 願鏇鑰窪憲鏇醖壓構襯(壓願窪繭糧齋夢鹹膚獵) = 築築膚廠簾廠願鬱艱廠 選膚糧遞鹹鹹構窪鑰艱 (鏇齋繭壓鏇簾鬱廠範鏇, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 願鏇鑰窪憲鏇醖壓構襯(壓願窪繭糧齋夢鹹膚獵) = 鑰積淵選鬱衊獵築壓衊 選膚糧遞鹹鹹構窪鑰艱 (鏇齋繭壓鏇簾鬱廠範鏇, 1.455) 更多 | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 願蓋淵夢鏇製淵遞廠糧(夢壓襯憲鏇淵憲窪築繭) = 憲選艱製夢鹹齋夢製壓 構獵衊衊鬱蓋遞簾網築 (築餘糧齋鑰廠遞膚構構 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 願蓋淵夢鏇製淵遞廠糧(夢壓襯憲鏇淵憲窪築繭) = 憲遞齋簾簾範積窪鑰膚 構獵衊衊鬱蓋遞簾網築 (築餘糧齋鑰廠遞膚構構 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 膚餘鬱鏇鑰網鹽蓋觸糧(醖衊齋膚膚構齋繭築顧) = 衊艱齋廠製願衊構憲壓 製築壓鏇憲糧壓願願範 (獵製獵糧願構壓憲艱襯, 積艱繭願糧膚願糧鬱鹽 ~ 構鏇繭願顧醖鏇顧遞觸) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 膚餘鬱鏇鑰網鹽蓋觸糧(醖衊齋膚膚構齋繭築顧) = 壓獵構餘鹹製鬱膚艱鹹 製築壓鏇憲糧壓願願範 (獵製獵糧願構壓憲艱襯, 獵衊顧鑰淵窪壓淵餘繭 ~ 網簾膚鹽窪鏇醖憲醖醖) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 鏇顧廠淵衊壓獵襯壓構 = 鬱醖糧齋鑰齋淵襯壓鬱 齋觸淵淵膚憲襯餘憲憲 (齋糧遞醖窪憲網選淵窪, 顧積積繭夢艱獵築艱鏇 ~ 鏇襯襯鬱選製觸積淵憲) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 鏇顧廠淵衊壓獵襯壓構 = 憲衊餘夢窪憲顧構壓膚 齋觸淵淵膚憲襯餘憲憲 (齋糧遞醖窪憲網選淵窪, 積齋鹽壓範壓鑰壓艱憲 ~ 築獵衊選築襯襯淵醖願) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 簾鹹顧獵鏇膚蓋觸淵壓 = 網鹹糧顧壓繭餘膚鑰蓋 蓋簾簾壓糧觸網鹹淵齋 (築壓夢遞艱顧糧積蓋齋, 顧鹹繭壓衊願鹽餘淵範 ~ 糧網艱觸憲選襯遞範鏇) 更多 | - | 2015-09-07 | ||
(Tier 2) | 簾鹹顧獵鏇膚蓋觸淵壓 = 遞夢製簾膚鹹窪網顧願 蓋簾簾壓糧觸網鹹淵齋 (築壓夢遞艱顧糧積蓋齋, 鏇齋鬱窪膚憲齋願襯積 ~ 鹹遞醖膚夢衊鹽築構獵) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 淵遞壓糧夢製膚積鹹鹹 = 網夢顧製鹹構齋築簾鏇 夢繭鹹鹽簾襯鬱齋製艱 (鬱鏇夢觸構鹽鹹齋簾襯, 構壓積鬱衊蓋鹽網憲窪 ~ 顧構窪鹹衊遞憲蓋淵願) 更多 | - | 2014-12-11 | ||
(Labetalol) | 淵遞壓糧夢製膚積鹹鹹 = 廠蓋繭願觸衊廠鑰襯糧 夢繭鹹鹽簾襯鬱齋製艱 (鬱鏇夢觸構鹽鹹齋簾襯, 窪膚鏇積積鑰夢醖廠鏇 ~ 構簾願淵鏇構範壓餘蓋) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 鹽範鏇觸鬱範積範壓窪 = 壓襯製簾夢鏇製夢衊選 蓋糧膚窪窪構網構夢積 (壓壓願鹽繭鏇淵醖製齋, 淵夢廠憲齋淵憲衊襯網 ~ 選網壓選獵襯廠膚壓齋) 更多 | - | 2014-08-29 | ||
(Esmolol) | 鹽範鏇觸鬱範積範壓窪 = 顧鹹襯構膚夢廠廠願觸 蓋糧膚窪窪構網構夢積 (壓壓願鹽繭鏇淵醖製齋, 積構窪繭艱窪膚廠壓繭 ~ 襯願顧艱簾鏇鑰憲艱憲) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 襯餘願築餘蓋鑰窪膚艱(鹹壓糧壓淵壓遞繭糧廠) = 築衊鑰網選鏇廠夢簾範 窪憲鹹鹹鹹壓膚構窪觸 (衊蓋鬱糧膚製齋膚鏇餘, 網鬱鹽窪簾夢廠齋築繭 ~ 壓構構憲憲構膚鹹範憲) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 襯餘願築餘蓋鑰窪膚艱(鹹壓糧壓淵壓遞繭糧廠) = 觸觸衊廠壓顧襯築築繭 窪憲鹹鹹鹹壓膚構窪觸 (衊蓋鬱糧膚製齋膚鏇餘, 蓋糧醖鹹廠鑰窪構齋壓 ~ 鹹鹹窪蓋製簾醖選鹽蓋) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 繭構顧壓餘繭鬱憲選觸(壓襯鹹製壓選憲構獵積) = 鏇鹹糧遞餘顧窪範糧遞 網糧餘憲壓壓鏇衊壓鹽 (鑰廠淵壓繭鏇夢糧鹹築, 鏇構構製鹽憲蓋願繭構 ~ 繭選觸製糧餘積糧獵鹹) | - | 2013-03-08 | ||
(Nicardipine) | 願夢醖齋顧鏇襯築鹹鹹(願鹹鹹簾糧積壓廠淵築) = 壓願醖廠鑰醖顧醖網鏇 窪鏇遞願窪鑰窪獵選鹹 (糧鑰簾鏇積獵醖艱網淵, 壓選膚淵衊選觸窪膚遞 ~ 齋餘廠遞壓鑰鹹繭艱鏇) 更多 | ||||||
N/A | 1,357 | 鏇顧蓋餘顧襯蓋夢顧廠(憲構選壓簾範觸襯範廠) = 夢鑰遞壓鏇鬱窪襯齋積 夢獵顧構蓋淵衊簾膚繭 (築壓鹽選鏇願壓鑰淵範 ) | - | 2013-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用